Postdoc fellowship in Immunotherapy of cancer

at  Oslo universitetssykehus

Postdoc fellowship in Immunotherapy of cancer
Section of Cellular Therapy, Translational Research Unit
Apply for position
(in new tab)
About the position
One postdoc fellowship in Immunotherapy of cancer: “Safety-Enhanced Chimeric Antigen Receptors (SECAR)” is available for a period of three years, from October 2024. This postdoc fellowship is supported by Helse Sør Øst.
The Section for Cellular Therapy counts 40 employees split in a clinical ward (GMP facility) and the Translational Research Unit (18 employees), which is developing pre-clinical solutions in cancer immunotherapy. We have produced the first Norwegian CAR molecule, anti-CD37CAR (Köksal, Dillard et al. 2019, Caulier et al. 2024), among a collection of almost 20 prepared either from our own stock of antibodies or from home-made antibodies. Our unit has the capacity to run full pre-clinical validations of TCR and CAR molecules: Radium-1 TCR was also the first ever tested in an academic clinical trial in Scandinavia (Radium-1 TCR, NCT03431311; Maggadottir et al. 2024). Our discoveries have led to the establishment of two biotechs: Ultimovacs and Zelluna AS. Our unit is located at the Oslo Cancer Cluster Incubator (https://occincubator.com/), next to the Radium Hospital, which represents an excellent environment for innovative development.
Oslo University Hospital is a workplace with great diversity. We believe this is essential to perform the tasks required of us. Therefore, we pursue diversity among our job applicants and encourage everyone to apply regardless of who you are and what background you have.
Key information
Application deadline:
01.09.2024
Employer:

CONTRACT

Percentage of full-time:
100
Webcruiter ID:
4840860291
Start date:
01.10.2024
Social sharing :
Share on x
Share on LinkedIn
Share on Facebook
Share by email
Project description:
CAR molecules have shown outstanding therapeutic effects for the treatment of otherwise fatal cancers; however, clinical benefits have been observed in restricted tumour types. The present project aims at delivering potent CAR molecules with safer profile for clinical use in cancer with a special focus (but not restricted to) AML, B-ALL and solid tumours with peritoneal metastases. The project is based on molecules that were recently published (Casey et al. 2023, Caulier et al. 2024) and their improvement. It also includes the identification of new constructs.
Qualifications:

The candidates must hold a PhD degree in Biology or Biochemistry. Other corresponding education in science (chemistry, physics, medicine, pharmacy, etc.) will be evaluated. Knowledge and practical experience in the following domains are necessary and should be documented:

• cellular biology (primary T-cell culture and functional assay)
• immunology (flowcytometry, MACS, PBMC isolation, ELISA)
• molecular biology (cloning, RNA isolation, RT-qPCR, retrovirus)
• animal experiment (FELASA-C or equivalent)

We are seeking motivated talents interested in working in cancer immunotherapy and contributing to the discovery of tomorrow’s drugs. The candidate should be highly interested in publishing and needs to be flexible, hardworking and independent. Our scientists work in different projects and teams, and the candidate will have to share and collaborate. Applicants must be fluent in English.

The application must include:

• Application letter (1 page maximum) containing a short description of the previous work where you document your experience with the required techniques
• CV (2 pages maximum) which should summarize education and previous positions. It should also include a list of laboratory techniques mastered, finalised and expected scientific publications and the name/contact details of 2 references
• Official copies of educational certificates (University level) with grades
• Please respect the document length and avoid using AI: exceeding document size, addition of unrequested documents and excessive use of AI will lead to disqualification.

Address:
Ullernchausseen 64, 0379 Oslo, Norway
Open directions

Please refer the Job description for details